Get Brochure

AREE stands for Autoridade Reguladora Estrangeira Equivalente or Equivalent Foreign Regulatory Authority . It refers to foreign regulatory authorities or international organizations whose regulatory practices align with ANVISA's (the Brazilian National Health Surveillance Agency). These authorities are responsible for ensuring that the products they approve for distribution meet recognized standards of quality, safety, and efficacy.

ANVISA uses assessments conducted by an AREE as part of its optimized analysis procedure, streamlining the approval process for drug products, biological products, vaccines, and medical devices by leveraging regulatory reliance. This practice allows ANVISA to expedite decisions on marketing authorizations and post-approval changes based on documentation and assessments from AREEs, provided they meet Brazilian regulatory requirements

What is the significance of AREE in Brazil’s Regulatory Landscape?

The significance of AREE in Brazil's regulatory landscape can be summarized as follows:

    1. Faster Approvals: By relying on evaluations from trusted foreign regulatory authorities (AREEs), ANVISA can expedite the approval of drugs, vaccines, biological products, and medical devices.

    2. Global Standards: AREEs ensure that approved products meet international quality, safety, and efficacy standards, aligning Brazil's regulatory practices with global norms.

    3. Regulatory Trust: ANVISA leverages regulatory trust with AREEs to reduce duplication of effort and focus on Brazil-specific needs, such as local epidemiology and target populations.

    4. Optimized Analysis: The optimized analysis procedure uses AREE assessments to simplify and speed up regulatory processes for marketing authorizations and post-approval changes.

    5. Focus on Priority Areas: ANVISA can direct its resources toward high-risk or Brazil-specific issues, as AREE assessments handle general quality and safety aspects.

    6. Transparency and Cooperation: AREEs follow transparent regulatory practices, preventing conflicts of interest and ensuring mutual trust through agreements like Memorandums of Understanding.

    7. Supports Innovation: Streamlined processes through AREEs encourage quicker market entry for innovative therapies and medical devices, benefiting public health.

    8. Consistency Across Markets: Products approved by AREEs are already assessed by globally recognized standards (e.g., EMA, FDA, WHO), ensuring consistency across international markets.

DDReg's Capabilities

DDReg possesses extensive expertise in navigating Brazil’s regulatory landscape, particularly in leveraging the AREE (Equivalent Foreign Regulatory Authority) framework. With a deep understanding of ANVISA’s reliance on assessments from trusted foreign regulatory authorities, DDReg ensures that pharmaceutical companies can expedite the approval process for drugs, vaccines, biological products, and medical devices.

How can we help you?
Contact our experts today !